Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

NEW ORLEANS — In back-to-back presentations on Monday with its Phase III data on a drug for pulmonary arterial hypertension, Merck

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mer­ck’s oral cho­les­terol-low­er­ing drug shows sim­i­lar ef­fi­ca­cy to in­jectable pre­de­ces­sors as it moves to PhI­II: #ACC23